
ALBO
Healthcare · Biotechnology · $915.9M market cap
Latest report
After the close
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Dec 31, 2022
EPS trend, 90 days to now · -7.7% over 90 days · 30-day revisions 0 up, 0 down
Beat estimates in 1 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| Nov 8, 2022 | After the close | -1.06 | -1.92 | -81.1% |
| Aug 15, 2022 | After the close | -1.65 | -2.04 | -23.6% |
| May 16, 2022 | After the close | -1.85 | -2.19 | -18.4% |
| Mar 1, 2022 | Before the open | -1.35 | -0.57 | +57.8% |
| Nov 4, 2021 | Before the open | -0.38 | 2.90 | +863.2% |
| Aug 5, 2021 | Before the open | -1.97 | -1.90 | +3.6% |
| May 6, 2021 | Before the open | -1.77 | -2.29 | -29.4% |
| Feb 25, 2021 | Before the open | -1.94 | -1.30 | +33.0% |
| Nov 5, 2020 | Before the open | -1.51 | -1.96 | -29.8% |
| Aug 6, 2020 | Before the open | -1.69 | -1.38 | +18.3% |
| May 7, 2020 | Before the open | -1.36 | -2.23 | -64.0% |
| Mar 2, 2020 | Before the open | -1.59 | -0.57 | +64.2% |
| Nov 6, 2019 | Before the open | -1.56 | -1.73 |
Albireo Pharma, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of novel bile acid modulators to treat orphan pediatric liver diseases and other liver or gastrointestinal diseases and disorders. The company offers Bylvay for the treatment of progressive familial intrahepatic cholestasis, as well as in Phase III clinical trial for treating biliary atresia,…
| -10.9% |
| Aug 8, 2019 | Before the open | -1.43 | -1.35 | +5.6% |
| May 9, 2019 | Before the open | -1.32 | -1.39 | -5.3% |
| Mar 6, 2019 | After the close | -1.16 | -1.34 | -15.5% |
| Nov 8, 2018 | After the close | -0.98 | -1.17 | -19.4% |
| Aug 7, 2018 | Before the open | -0.95 | -1.22 | -28.4% |
| May 10, 2018 | After the close | 1.77 | -0.15 | -108.5% |
| Mar 15, 2018 | Before the open | -0.80 | -0.55 | +31.3% |